(Q37810084)

23 August 2017

title

Temsirolimus for the treatment of mantle cell lymphoma (English)

1 reference

23 August 2017

Georg Hess

1

1 reference

23 August 2017

publication date

1 December 2009

1 reference

Expert Review of Hematology

23 August 2017

published in

1 reference

23 August 2017

volume

2

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

631-640

1 reference

Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.

23 August 2017

cites work

1 reference

Current management of mantle cell lymphoma

21 January 2018

1 reference

How I treat mantle cell lymphoma.

21 January 2018

1 reference

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

21 January 2018

1 reference

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

21 January 2018

1 reference

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

21 January 2018

1 reference

Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network

21 January 2018

1 reference

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

21 January 2018

1 reference

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

21 January 2018

1 reference

Molecular basis of mantle cell lymphoma

21 January 2018

1 reference

Update on the molecular biology of mantle cell lymphoma

21 January 2018

1 reference

Advances in the understanding of mantle cell lymphoma

21 January 2018

1 reference

Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma

21 January 2018

1 reference

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma

21 January 2018

1 reference

Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas

21 January 2018

1 reference

mTOR, translation initiation and cancer

21 January 2018

1 reference

Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma

21 January 2018

1 reference

Syk-dependent mTOR activation in follicular lymphoma cells.

21 January 2018

1 reference

Current treatment approaches for mantle-cell lymphoma

21 January 2018

1 reference

Therapeutic options in mantle cell lymphoma

21 January 2018

1 reference

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).

21 January 2018

1 reference

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

21 January 2018

1 reference

Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK).

21 January 2018

1 reference

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

21 January 2018

1 reference

Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond

21 January 2018

1 reference

Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

21 January 2018

1 reference

Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma

21 January 2018

1 reference

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

21 January 2018

1 reference

Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma

21 January 2018

1 reference

Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma

21 January 2018

1 reference

mTOR pathway and mTOR inhibitors as agents for cancer therapy

21 January 2018

1 reference

Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications

21 January 2018

1 reference

Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus

21 January 2018

1 reference

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

21 January 2018

1 reference

In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites

21 January 2018

1 reference

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

21 January 2018

1 reference

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

21 January 2018

1 reference

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

21 January 2018

1 reference

A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL.

21 January 2018

1 reference

Leukemic involvement is a common feature in mantle cell lymphoma

21 January 2018

1 reference

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/EHM.09.57

1 reference

23 August 2017

1 reference